Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 1
2000 1
2002 3
2003 2
2005 3
2006 1
2007 1
2008 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 1
2018 1
2019 1
2020 3
2021 11
2022 13
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Potent human broadly SARS-CoV-2-neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2.
Planchais C, Fernández I, Bruel T, de Melo GD, Prot M, Beretta M, Guardado-Calvo P, Dufloo J, Molinos-Albert LM, Backovic M, Chiaravalli J, Giraud E, Vesin B, Conquet L, Grzelak L, Planas D, Staropoli I, Guivel-Benhassine F, Hieu T, Boullé M, Cervantes-Gonzalez M, Ungeheuer MN, Charneau P, van der Werf S, Agou F; French COVID Cohort Study Group; CORSER Study Group; Dimitrov JD, Simon-Lorière E, Bourhy H, Montagutelli X, Rey FA, Schwartz O, Mouquet H. Planchais C, et al. Among authors: staropoli i. J Exp Med. 2022 Jul 4;219(7):e20220638. doi: 10.1084/jem.20220638. Epub 2022 Jun 15. J Exp Med. 2022. PMID: 35704748 Free PMC article.
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, Bolland WH, Porrot F, Staropoli I, Lemoine F, Péré H, Veyer D, Puech J, Rodary J, Baele G, Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina-Bokalanga T, Martí-Carreras J, Cuypers L, Sève A, Hocqueloux L, Prazuck T, Rey FA, Simon-Loriere E, Bruel T, Mouquet H, André E, Schwartz O. Planas D, et al. Among authors: staropoli i. Nature. 2022 Feb;602(7898):671-675. doi: 10.1038/s41586-021-04389-z. Epub 2021 Dec 23. Nature. 2022. PMID: 35016199
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
Bruel T, Stéfic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, Guivel-Benhassine F, Bolland WH, Planas D, Hadjadj J, Handala L, Planchais C, Prot M, Simon-Lorière E, André E, Baele G, Cuypers L, Mouthon L, Mouquet H, Buchrieser J, Sève A, Prazuck T, Maes P, Terrier B, Hocqueloux L, Schwartz O. Bruel T, et al. Among authors: staropoli i. Cell Rep Med. 2022 Dec 20;3(12):100850. doi: 10.1016/j.xcrm.2022.100850. Epub 2022 Nov 17. Cell Rep Med. 2022. PMID: 36450283 Free PMC article.
Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, Simon-Loriere E, Veyer D, Prazuck T, Péré H, Schwartz O. Planas D, et al. Among authors: staropoli i. Nat Commun. 2023 Feb 14;14(1):824. doi: 10.1038/s41467-023-36561-6. Nat Commun. 2023. PMID: 36788246 Free PMC article.
Divergent adaptive immune responses define two types of long COVID.
Kervevan J, Staropoli I, Slama D, Jeger-Madiot R, Donnadieu F, Planas D, Pietri MP, Loghmari-Bouchneb W, Alaba Tanah M, Robinot R, Boufassa F, White M, Salmon-Ceron D, Chakrabarti LA. Kervevan J, et al. Among authors: staropoli i. Front Immunol. 2023 Jul 20;14:1221961. doi: 10.3389/fimmu.2023.1221961. eCollection 2023. Front Immunol. 2023. PMID: 37559726 Free PMC article.
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: staropoli i. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962
Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Dufloo J, Grzelak L, Staropoli I, Madec Y, Tondeur L, Anna F, Pelleau S, Wiedemann A, Planchais C, Buchrieser J, Robinot R, Ungeheuer MN, Mouquet H, Charneau P, White M, Lévy Y, Hoen B, Fontanet A, Schwartz O, Bruel T. Dufloo J, et al. Among authors: staropoli i. Cell Rep Med. 2021 May 18;2(5):100275. doi: 10.1016/j.xcrm.2021.100275. Epub 2021 Apr 20. Cell Rep Med. 2021. PMID: 33899033 Free PMC article.
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
Planas D, Staropoli I, Michel V, Lemoine F, Donati F, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, Dehan O, Avon L, Boland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, Lina B, Trouillet-Assant S; COVID-SER study group; Hocqueloux L, Prazuck T, Simon-Loriere E, Schwartz O. Planas D, et al. Among authors: staropoli i. bioRxiv [Preprint]. 2024 Feb 9:2023.11.20.567873. doi: 10.1101/2023.11.20.567873. bioRxiv. 2024. PMID: 38045308 Free PMC article. Preprint.
Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Henry-Bolland W, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: staropoli i. medRxiv [Preprint]. 2023 May 30:2023.05.25.23290512. doi: 10.1101/2023.05.25.23290512. medRxiv. 2023. PMID: 37398037 Free PMC article. Preprint.
Targeting CCR5 trafficking to inhibit HIV-1 infection.
Boncompain G, Herit F, Tessier S, Lescure A, Del Nery E, Gestraud P, Staropoli I, Fukata Y, Fukata M, Brelot A, Niedergang F, Perez F. Boncompain G, et al. Among authors: staropoli i. Sci Adv. 2019 Oct 16;5(10):eaax0821. doi: 10.1126/sciadv.aax0821. eCollection 2019 Oct. Sci Adv. 2019. PMID: 31663020 Free PMC article.
57 results